Transverse Myelitis Treatment Market: Rise in prevalence of transverse myelitis is anticipated to drive the market – BioSpace

Transverse myelitis is a rare inflammatory disease. It is caused by inflammation of the spinal cord. Generally, transverse myelitis damages the insulating material covering nerve cell fibers (myelin).

Signs and symptoms of transverse myelitis include pain, weakness in arms or legs, abnormal sensations, and bladder & bowel problems. Patients suffering from transverse myelitis report coldness or burning, numbness, and tingling. The exact cause of transverse myelitis is unknown. According to PubMed studies, transverse myelitis can be caused by multiple sclerosis, autoimmune disorders, Devic's disease, and infections of the gastrointestinal tract. Major complications of transverse myelitis are sexual dysfunction, stiffness, tightness or painful spasms, depression, or anxiety.

Read Report Overview - https://www.transparencymarketresearch.com/transverse-myelitis-treatment-market.html

Doctors or professionals can diagnose transverse myelitis based on medical history and tests. Common diagnostic tests for transverse myelitis are lumbar puncture (spinal tap), blood tests, and magnetic resonance imaging (MRI).

Rise in prevalence of transverse myelitis across the world is anticipated to drive the global transverse myelitis treatment market during the forecast period. A rise in government prioritization of drugs for rare disorders is also expected to propel the global market in the near future. Moreover, shortage of health care experts in Latin America and Middle East & Africa hampers the growth of the transverse myelitis treatment market in the regions. Nevertheless, increase in government funding for diagnostic procedures is likely to augment the transverse myelitis treatment market. Organizations supporting the treatment of this disease globally are the Genetic and Rare Diseases (GARD) Information Center, the NIH/National Institute of Neurological Disorders and Stroke, the Academy of Spinal Cord Injury Professionals, Inc., and the Transverse Myelitis Association.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=56202

The global transverse myelitis treatment market can be segmented based on treatment, end-user, and region. In terms of treatment, the market can be bifurcated into drugs and therapies. The drugs segment can be classified into intravenous steroids, antiviral medication, pain medication, and others. The therapies segment can be categorized into physical therapy, occupational therapy, and psychotherapy. Methylprednisolone and dexamethasone are the common steroids used for the treatment of transverse myelitis. Occupational therapy and physical therapy have been effective in some patients. Chronic pain is a common complication of transverse myelitis. Doctors recommend common pain relievers such as acetaminophen, naproxen and ibuprofen.

Request for Analysis of COVID-19 Impact on Transverse Myelitis Treatment Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=56202

In terms of end-user, the global transverse myelitis treatment market can be divided into hospitals, special clinics, and others. The hospitals segment held significant share of the market in 2017.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=56202

Based on region, the global transverse myelitis treatment market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America accounted for major share of the global market in 2017, followed by Europe and Asia Pacific. The U.S. held significant share of the market in North America in terms of revenue. The transverse myelitis treatment market in Asia Pacific is growing rapidly due to increase in the number of patients suffering from the disorder. Better health care infrastructure, economic growth, rise in the number of insurance payers, expanding & developing private health care sector, and increase in awareness among people about transverse myelitis treatment are expected to propel the market in the region in the next few years. The transverse myelitis treatment market in Latin America and Middle East & Africa is projected to expand at a moderate growth rate from 2018 to 2026.

Pre Book Transverse Myelitis Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=56202&ltype=S

Key players operating in the global transverse myelitis treatment market include Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., WOCKHARDT, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Baxter, Amerigen Pharmaceuticals Limited, and Novartis AG.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: https://www.transparencymarketresearch.com/

Follow this link:
Transverse Myelitis Treatment Market: Rise in prevalence of transverse myelitis is anticipated to drive the market - BioSpace